20 Nov 2026, 08:36
Director Interests—
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 20 Nov 2026, 08:36 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 20 Nov 2026, 08:36 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 20 Nov 2026, 08:35 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 20 Nov 2026, 08:26 | Cleansing Statement | Securities Administration | — | 06018 | |
| 20 Nov 2026, 08:25 | Application for quotation of securities - NOX | Securities Administration | — | 06020 | |
| 19 Nov 2026, 14:45 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 17 Nov 2026, 15:10 | Notice of Extraordinary General Meeting/Proxy Form | Meetings & Governance | — | 08002, 08004 | |
| 17 Nov 2026, 14:56 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 17 Nov 2026, 08:28 | Noxopharm 2026 AGM Corporate Presentation | Presentations | — | 03026, 15002 | |
| 17 Nov 2026, 08:28 | Noxopharm 2026 AGM Chair's Address | Letters & Addresses | — | 15002 | |
| 12 Nov 2026, 13:44 | Noxopharm receives $1.4 million R&D tax incentive rebate | Periodic Reports | MS | 03014 | |
| 6 Nov 2026, 08:24 | Noxopharm Investor Webinar | Company Administration | — | 12008 | |
| 5 Nov 2026, 10:19 | Cleansing Statement | Securities Administration | — | 06018 | |
| 5 Nov 2026, 10:04 | Application for quotation of securities - NOX | Securities Administration | — | 06020 | |
| 3 Nov 2026, 08:40 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 2 Nov 2026, 14:34 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 2 Nov 2026, 10:53 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 2 Nov 2026, 10:53 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 2 Nov 2026, 10:53 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 2 Nov 2026, 10:53 | Reinstatement to Quotation | Reinstatement | MS | 09002 | |
| 2 Nov 2026, 10:53 | Noxopharm Successfully Raises $1.5 Million via Placement | Capital Raising | MS | 06003, 06017 | |
| 29 Oct 2026, 08:58 | Voluntary Suspension | Trading Halt / Suspension | MS | 09001 | |
| 27 Oct 2026, 08:57 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 16 Oct 2026, 11:50 | 2026 AGM Letter of Access, Notice of Meeting and Proxy | Meetings & Governance | — | 08001, 08004 | |
| 16 Oct 2026, 10:45 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 16 Oct 2026, 10:32 | Annual Report to shareholders | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 8 Oct 2026, 08:15 | FDA feedback supports SOF-SKN Phase II plans | Company Update | — | 11001 | |
| 30 Sept 2026, 16:05 | Audited Financial Statements | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 14 Sept 2026, 08:23 | SOF-SKN to progress to extension study in CLE patients | Company Update | — | 11001 | |
| 4 Sept 2026, 08:11 | Investor Presentation September 2026 | Presentations | — | 03026 | |
| 1 Sept 2026, 09:36 | Novel oligonucleotides data presented at Options Conference | Company Update | MS | 11001 | |
| 28 Aug 2026, 16:34 | Appendix 4E - Preliminary Financial Report | Financial Results | MS | 03003 | |
| 26 Aug 2026, 08:06 | New preclinical data supports immuno-oncology approach | Company Update | MS | 11001 | |
| 4 Aug 2026, 08:18 | New study further validates Noxopharms cancer pipeline | Company Update | — | 11001 | |
| 22 July 2026, 08:26 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 7 July 2026, 09:34 | Pre-IND meeting request with US FDA | Company Update | — | 11001 | |
| 2 July 2026, 08:15 | Sofr platform versatility shown via childbirth MRFF grant | Company Update | — | 11001, 12008 | |
| 1 July 2026, 09:50 | Fast-tracking of cancer program via novel animal model | Company Update | — | 11001 | |
| 9 June 2026, 08:29 | SOF-SKN manufacturing begins to ensure clinical trial readi | Company Update | MS | 11001 | |
| 1 June 2026, 16:23 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 26 May 2026, 08:21 | New data confirms cancer-fighting potential | Company Update | MS | 11001 | |
| 20 May 2026, 09:21 | Noxopharms Sofra assets to be presented at global conference | Company Update | MS | 11001 | |
| 8 May 2026, 09:28 | Proposed issue of securities - NOX | Securities Administration | — | 06013 | |
| 6 May 2026, 08:13 | Noxopharm progresses US regulatory strategy | Company Update | MS | 11001 | |
| 1 May 2026, 09:08 | New data shows SOF-SKN active ingredient efficacy | Company Update | MS | 11001 | |
| 30 Apr 2026, 08:18 | New Company Secretary appointed | Company Administration | — | 12007 | |
| 27 Apr 2026, 08:21 | Innovative collaboration further expands Sofra platform | Company Update | MS | 11001 | |
| 24 Apr 2026, 09:23 | March 2026 Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 22 Apr 2026, 08:35 | Positive SOF-SKN dosing data shows prolonged skin retention | Company Update | MS | 11001 | |
| 15 Apr 2026, 09:27 | Noxopharm appoints Dr Olivier Laczka as new CEO | Company Administration | MS | 12019 |